This category page covers biotechnology and pharmaceutical companies developing heat shock protein (HSP) modulators, pharmacological chaperones, and protein folding therapies for Alzheimer's disease (AD). Protein misfolding and aggregation — of amyloid-beta and tau — are central pathological features of AD, and the cellular proteostasis network that normally handles these proteins becomes progressively impaired with age and disease. Enhancing the chaperone system pharmacologically represents a disease-modifying strategy that addresses the root cause of protein pathology rather than downstream symptoms[@bukau2018][@kim2013].
The main therapeutic approaches in this space include:
Mechanism: Allosteric pharmacological chaperones targeting glucocerebrosidase (GCase) via SEE-Tx platform
Clinical Stage: Phase 1b (GT-02287 in GBA1-PD and idiopathic PD)
This category page covers biotechnology and pharmaceutical companies developing heat shock protein (HSP) modulators, pharmacological chaperones, and protein folding therapies for Alzheimer's disease (AD). Protein misfolding and aggregation — of amyloid-beta and tau — are central pathological features of AD, and the cellular proteostasis network that normally handles these proteins becomes progressively impaired with age and disease. Enhancing the chaperone system pharmacologically represents a disease-modifying strategy that addresses the root cause of protein pathology rather than downstream symptoms[@bukau2018][@kim2013].
The main therapeutic approaches in this space include:
Mechanism: Allosteric pharmacological chaperones targeting glucocerebrosidase (GCase) via SEE-Tx platform
Clinical Stage: Phase 1b (GT-02287 in GBA1-PD and idiopathic PD)
Background: Gain Therapeutics uses its proprietary SEE-Tx (Site-Directed Excipient Engineering) computational platform to identify small molecule chaperones that stabilize misfolded proteins. While the company's lead program GT-02287 targets GBA1-associated Parkinson's disease, Gain is also exploring GCase modulation in Alzheimer's disease where GCase dysfunction may contribute to amyloid pathology and lysosomal impairment[@gain2026][@gain2026a].
Key Programs:
Company: [Gain Therapeutics profile](/companies/gain-therapeutics)
Mechanism: HSP70 modulators and aggregation inhibitors for synucleinopathies
Clinical Stage: IND-enabling studies (IDN-001)
Background: Iduna Therapeutics is developing small molecule chaperone modulators for Parkinson's disease and related neurodegenerative disorders. The company's lead candidate IDN-001 directly enhances HSP70 activity to promote clearance of misfolded proteins including alpha-synuclein and potentially tau. While focused on synucleinopathies (PD, DLB, MSA), Iduna's platform is theoretically applicable to AD where tau pathology represents a related proteostasis challenge[@iduna-website][@hsp70-alpha-syn].
Key Programs:
Mechanism: HSP90 inhibitors for neuroprotection
Clinical Stage: Preclinical / Research
Background: Axxonis Pharma AG, acquired by Novartis in 2017, developed early HSP90 inhibitors for neurodegenerative disease applications. HSP90 maintains client proteins in folding-competent states, and inhibiting HSP90 triggers proteasomal degradation of aggregation-prone proteins. While Axxonis is best known for safinamide (MAO-B inhibitor, marketed as Xadago), the company's prior work on HSP90 inhibitors in neurodegeneration remains relevant to the AD therapeutic landscape[@shirotani2020][@axxonis2024].
Key Programs:
Mechanism: Targeted HSP90 modulation for protein aggregation diseases
Clinical Stage: Research / Preclinical
Background: Cyclo Therapeutics is developing approaches that couple HSP90 modulation with targeted delivery mechanisms for improved CNS penetration. The challenge with early HSP90 inhibitors was limited brain exposure and hepatotoxicity. Cyclo's approach focuses on developing brain-penetrant HSP90 modulators with improved therapeutic windows for neurodegenerative applications[@mccormick2023].
Key Programs:
Mechanism: Autophagy-lysosome pathway enhancers and proteostasis modulators
Clinical Stage: Preclinical
Background: Casma Therapeutics is developing small molecules that enhance the autophagy-lysosome pathway to clear protein aggregates. While focused broadly on proteostasis, their approach intersects with the HSP70/HSP90 system through shared client proteins and overlapping pathways. Autophagy and chaperone-mediated clearance represent complementary arms of the cellular protein quality control network[@casma2024].
Company: [Casma Therapeutics](https://www.casmatherapeutics.com)
Mechanism: Chaperone-mediated autophagy (CMA) enhancement
Clinical Stage: Preclinical
Background: Life Biosciences is focused on enhancing chaperone-mediated autophagy, a selective degradation pathway for proteins with KFERQ-like motifs. CMA becomes impaired in aging and neurodegenerative disease, and restoring this pathway could selectively clear aggregating proteins like tau while sparing normal cellular components. Their LISC-52 program targets CMA upregulation in aging-related conditions[@life2024].
Company: [Life Biosciences](https://www.lifebiosciences.com)
| Company | Mechanism | Stage | Notes |
|---------|-----------|-------|-------|
| Samus Therapeutics | PU-H71 (HSP90 inhibitor) | Preclinical | Brain-penetrant; AD/PD programs |
| Orphazyme | Arimoclomol (HSF1 activator) | Phase 2/3 (ALS) | HSP70/HSP90 co-inducer |
| AbbVie | HSP90 modulators | Discovery | Broad neurodegeneration focus |
| Roche | Lysosomal acidifiers / proteostasis | Preclinical | V-ATPase modulators |
| Navitor Pharmaceuticals | mTORC1 inhibition | Phase 1 | Autophagy release (overlapping) |
| Acumen Pharmaceuticals | Autophagy enhancers | Discovery | Novel small molecules |
In Alzheimer's disease, the proteostasis network becomes progressively impaired through multiple mechanisms:
HSP70 (HSPA family) is the central molecular chaperone:
| Strategy | Approach | Examples |
|----------|---------|----------|
| Direct HSP70 modulators | Allosteric activation of existing chaperone | Iduna IDN-001 |
| HSF1 activators | Increase endogenous chaperone expression | Arimoclomol, Geranylgeranylacetone |
| HSP90 inhibitors | Trigger client degradation via proteasome | PU-H71, Geldanamycin derivatives |
| Pharmacological chaperones | Stabilize specific misfolded proteins | Gain SEE-Tx GCase modulators |
| CMA enhancers | Upregulate chaperone-mediated autophagy | Life Biosciences LISC-52 |
| Combination approaches | Chaperones + autophagy modulators | Multiple programs |
HSP70 can directly prevent aggregation of misfolded proteins through steric shielding of hydrophobic regions[@hsp70-alpha-syn]. In cellular and animal models:
HSP90 plays paradoxical roles in neurodegeneration[@shirotani2020]:
The proteostasis network naturally declines with age[@proteostasis-network]:
While no HSP modulators are approved for neurodegenerative disease, the approach has precedent:
| Trial ID | Drug | Phase | Population | Status |
|----------|------|-------|------------|--------|
| NCT06732180 | GT-02287 (Gain) | Phase 1b | GBA1-PD / idiopathic PD | Recruiting |
| — | IDN-001 (Iduna) | Preclinical | PD | IND-enabling |
| — | PU-H71 (Samus) | Preclinical | AD / PD | Research |
| NCT02772368 | Arimoclomol (Orphazyme) | Phase 2/3 | ALS | Completed |
| — | NV-2526 (Navitor) | Phase 1 | Neurological | Phase 1 |
The case for chaperone modulation in Alzheimer's disease:
| Company | Approach | Stage | Differentiation |
|---------|---------|-------|-----------------|
| Gain Therapeutics | GCase allosteric chaperones | Phase 1b | Computational platform; LSD crossover |
| Iduna Therapeutics | HSP70 modulators | Preclinical | Direct chaperone activation; oral |
| Axxonis Pharma | HSP90 inhibitors | Preclinical | Novartis-backed; legacy platform |
| Cyclo Therapeutics | Targeted HSP90 | Research | CNS-targeted delivery |
| Casma Therapeutics | Autophagy-proteostasis | Preclinical | Direct autophagy machinery |
| Life Biosciences | CMA enhancement | Preclinical | Selective degradation pathway |